French Doctors Reassured On Reforms

2 January 1995

French Premier Edouard Balladur has told doctors that he believes there is a chance of "lasting success" in the control of health spending through the activities of medical practitioners.

Speaking shortly after the publication of the White Paper on the health service (see page 11), whose scenario of possible direct economic regulation of the health service has already drawn protests from doctors, he urged health care professionals to "mobilize" in order to avoid recourse to "excessively restrictive measures." Mr Balladur also said the 1994-95 social security deficit of 105 billion French francs ($19.4 billion) was too high, but that it was not impossible to reach a balance in the general security system by 1997.

Meantime, Social Affairs Minister Simone Weil has asked doctors to prescribe less expensive but equally effective drugs. Since January 1994, efforts to control drug spending have begun to show results, with reimbursable drug spending growth down to 2.8% compared with 6%-7% in the three previous years.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight